Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

Rhea-AI Summary

Stereotaxis (NYSE: STXS) will release fourth quarter and full year 2025 financial results on Monday, March 9, 2026 after U.S. market close and host a conference call and webcast at 4:30 p.m. ET.

Investors can dial in using U.S./Canada number 800-715-9871 or international 646-307-1963 with pass code 8365695, and a webcast and one-month phone replay will be available via the company investor relations site.

News Market Reaction

-0.49%

1 alert

-0.49% News Effect

On the day this news was published, STXS declined 0.49%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: March 9, 2026 Conference call time: 4:30 p.m. ET Patients treated: over 150,000 patients

3 metrics

Earnings release date March 9, 2026 Scheduled 2025 Q4 and full-year financial results release

Conference call time 4:30 p.m. ET Start time for Q4 and full-year 2025 earnings call

Patients treated over 150,000 patients Cumulative global use of Stereotaxis technology

Market Reality Check

Price: $2.02 Vol: Volume 370,686 is 0.72x t...

normal vol

$2.02 Last Close

Volume Volume 370,686 is 0.72x the 20-day average volume of 515,489, showing subdued trading ahead of the earnings date. normal

Technical Shares at $2.03 are trading below the 200-day MA of $2.49, reflecting a weaker longer-term trend into the earnings report.

Peers on Argus

STXS was down 3.33% pre-announcement while several peers like STSS (-2.35%), NYX...

STXS was down 3.33% pre-announcement while several peers like STSS (-2.35%), NYXH (-1.68%), and MBOT (-0.99%) also traded lower, but no coordinated momentum was flagged by the sector scanner.

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	New EP program	Positive	+4.4%	German hospital established a Genesis robotic heart arrhythmia program.
Jan 06	FDA approval	Positive	+8.1%	FDA approved MAGiC ablation catheter for robotic electrophysiology use.
Nov 24	Conference participation	Positive	+1.7%	Participation in major healthcare conference highlighting growth and milestones.
Nov 11	Q3 2025 earnings	Positive	+2.1%	Reported Q3 results with >20% expected 2025 revenue growth and new clearances.
Nov 10	FDA clearance	Positive	+2.6%	GenesisX robotic system received FDA 510(k) clearance and limited launch began.

Pattern Detected

Recent company-specific news, including FDA clearances, program expansions, and Q3 earnings, has generally been followed by positive next-day price reactions.

Recent Company History

Over the last several months, Stereotaxis reported multiple positive developments. An FDA approval for the MAGiC ablation catheter on Jan 6, 2026 and a new German robotic EP program on Feb 9, 2026 saw +8.05% and +4.43% next-day moves, respectively. The Q3 2025 earnings release on Nov 11, 2025 and GenesisX FDA clearance on Nov 10, 2025 also produced modest gains. Today’s earnings-date announcement fits into a cadence of ongoing product, clinical, and financial updates.

Market Pulse Summary

This announcement simply schedules Stereotaxis’ release of its 2025 fourth quarter and full-year res...

Analysis

This announcement simply schedules Stereotaxis’ release of its 2025 fourth quarter and full-year results and related conference call. In context, it follows several positive milestones, including FDA approvals and new robotic program installations, which previously saw favorable price reactions. When those results are reported, investors will likely focus on revenue growth versus prior quarters, progress in commercializing GenesisX and MAGiC, cash levels, and any updated commentary on future regulatory or commercialization milestones.

Key Terms

surgical robotics, minimally invasive endovascular intervention, webcast

3 terms

surgical robotics technical

"a pioneer and global leader in surgical robotics for minimally invasive endovascular"

Surgical robotics are computer-guided machines—robotic arms, cameras and software—that assist surgeons by increasing steadiness, precision and access during operations, acting like a highly controlled extension of a surgeon’s hands. Investors pay attention because these systems can reshape hospital spending, create recurring revenue from instruments, software and service contracts, and their commercial success depends on clinical outcomes, regulatory approval and how quickly hospitals adopt the technology.

minimally invasive endovascular intervention medical

"surgical robotics for minimally invasive endovascular intervention, today announced"

A minimally invasive endovascular intervention is a medical procedure that treats blood vessel problems from inside the vessel using thin tubes, wires and small tools threaded through a tiny puncture instead of large surgical cuts; think of fixing plumbing by inserting tools through the pipes rather than tearing out walls. It matters to investors because these procedures typically cut hospital stays, lower complication rates and can expand patient access, which affects device sales, procedure volumes and healthcare costs.

webcast technical

"The Company will host a conference call and webcast at 4:30 p.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

What:	Stereotaxis fourth quarter and full year 2025 financial results conference call
When:	Monday, March 9, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Dial In Number:	To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 8365695.
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
Call Replay:	A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery                    
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

When will Stereotaxis (STXS) report fourth quarter and full year 2025 results?

Stereotaxis will report results on Monday, March 9, 2026 after U.S. market close at 4:30 p.m. ET. According to Stereotaxis, management will discuss financial results and corporate developments during the conference call and webcast that day.

How can investors join the Stereotaxis (STXS) March 9, 2026 conference call?

Investors can dial 800-715-9871 (US/Canada) or 646-307-1963 (International) and enter pass code 8365695. According to Stereotaxis, the call begins at 4:30 p.m. ET and a live webcast will also be available on the investor relations website.

Where can I access the Stereotaxis (STXS) live webcast and replay for the March 9, 2026 call?

The live webcast and replay are available on Stereotaxis’ investor relations website at http://ir.stereotaxis.com/. According to Stereotaxis, a phone replay will also be available for one month beginning about four hours after the call ends.

What will Stereotaxis (STXS) management cover during the March 9, 2026 call?

Management will discuss the company’s fourth quarter and full year 2025 financial results and corporate developments. According to Stereotaxis, the presentation aims to review performance metrics and recent business updates with investors and analysts.

Who should investors contact for questions about Stereotaxis (STXS) investor relations?

Investors can reach the company at 314-678-6100 or via Investors@Stereotaxis.com for investor queries. According to Stereotaxis, David L. Fischel and Kimberly Peery are listed as investor contacts for further information.